Dr. Mei Yee Koh's research lab focuses on understanding how obesity influences liver cancer development, particularly through a protein called HAF. They explore the links between metabolic diseases, like fatty liver disease, and hepatocellular carcinoma, aiming to identify new ways to prevent or treat this aggressive cancer. By studying how HAF functions at the molecular level, the lab hopes to uncover new biomarkers and therapeutic targets that can improve outcomes for patients with liver cancer.

Dr. Eric W Schmidt's lab focuses on discovering new antibacterial drugs and understanding the chemical diversity found in nature, particularly from marine animals and their symbiotic bacteria. They aim to develop innovative compounds that can combat multidrug-resistant pathogens and enhance our understanding of pain signaling in the sensory nervous system. By exploring the unique chemistry of these organisms, the lab hopes to advance drug discovery technologies and improve therapeutic approaches for various diseases.

Dr. Alphonsus Ng's lab focuses on understanding Type 1 Diabetes (T1D) by analyzing extracellular vesicles (EVs) released into the bloodstream. Their work involves developing advanced micro-nanotechnologies to identify potential biomarkers for T1D, which could lead to better diagnosis and treatment options. The lab combines expertise in immunology, molecular analysis, and engineering to study the unique molecular signatures from pancreatic islet cells and T cell activity in diabetes.

Dr. Mingnan Chen's lab focuses on understanding how specific immune cell interactions influence treatment outcomes for Type 1 Diabetes (T1D). The research investigates how a new antibody therapy can effectively target harmful immune cells while minimizing adverse effects. By exploring the immune environment surrounding T1D and developing new antibody-based treatments, the goal is to enhance the safety and effectiveness of therapies for T1D patients.